title: Are triptans with enhanced lipophilicity used for the acute treatment of migraine associated with an increased consulting rate for depressive illness?
abstract: 1997, sumatriptan-treated migraineurs had significantly higher depression PCRs (22.3%) compared with non-triptan users (19.3%), a difference of 6.4% (95% confidence interval (CI) 4.6-8.4%, P < 0.001). In the year (April 1997 to March 1998) following the launch of the TELs, depression PCRs were significantly higher among patients using these compounds compared with sumatriptan-treated patients (5.1%, CI 1.8-12.0%, P < 0.05). However, after taking account of prior depression (odds ratio (OR) 6.45, 95% CI 3.63-11.43), TELs were not significantly associated with depression (OR 0.27, 95% CI 0.03-2.13). Furthermore, rates of newly diagnosed depression after treatment were similar in the two triptan groups (sumatriptan 4.2%; TELs 3.9%). Although, the TELs are being prescribed to patients with higher pre-existing rates of depression, they are not associated with subsequently increased consulting for depressive illness compared with patients taking sumatriptan. This study highlights the potential to use GPRD to test targeted hypotheses exploring pharmacovigilance issues for patients using new medicines.
authors.affiliation: Primary Care Sciences Research Centre, Keele University, London, UK. d.millson@keele.ac.uk
authors.forename: D
authors.initials: D
authors.lastname: Millson
authors.forename: M
authors.initials: M
authors.lastname: Frischer
authors.forename: P
authors.initials: P
authors.lastname: Croft
authors.forename: P J
authors.initials: PJ
authors.lastname: Goadsby
mesh_terms: D015331:Cohort Studies; D003863:Depression / Q000139:chemically induced* / Q000628:therapy*; D005260:Female; D006801:Humans; D007211:Indoles / Q000009:adverse effects*; D008297:Male; D008881:Migraine Disorders / Q000188:drug therapy*; D023303:Oxazolidinones / Q000009:adverse effects*; D010880:Piperidines / Q000009:adverse effects*; D012017:Referral and Consultation / Q000706:statistics & numerical data*; D012044:Regression Analysis; D017366:Serotonin Receptor Agonists / Q000009:adverse effects*; D018170:Sumatriptan / Q000009:adverse effects; D014363:Tryptamines
chemical_list: D007211:Indoles; D023303:Oxazolidinones; D010880:Piperidines; D017366:Serotonin Receptor Agonists; D014363:Tryptamines; C089750:zolmitriptan; D018170:Sumatriptan; C106783:naratriptan